Volume 21, Issue 2 (2018)                   mjms 2018, 21(2): 85-94 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shafighian F, Nazarian S, Amani J, Fahimi H. Evaluation of Oral and Injection Immunization with Chitosan Nanoparticles ‎Containing HER-2 antigene. mjms. 2018; 21 (2) :85-94
URL: http://mjms.modares.ac.ir/article-30-1656-en.html
1- Pharmaceutical Sciences Research Center, Pharmaceutical Sciences Branch, Islamic Azad University, ‎Tehran, Iran ‎
2- Biology Department, Basic Sciences Faculty, Imam Hossain University, Tehran, Iran , Nazarian56@gmail.com
3- Applied Microbiology Research Center, System biology and poisonings institute, Baqiyatallah ‎University of Medical Sciences, Tehran, Iran
4- Molecular and Cellular Sciences Department, Advanced Sciences and Technology Faculty, ‎Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran‎
Abstract:   (8066 Views)

Aims: Breast cancer is the most common cancer among women around the world and in Iran and 22% of all cancers in women is included.
About 30% of cases with breast cancers are due to the proliferation or excessive expression of HER-2 protein. Chitosan is an environmentally friendly combination, due to its minimal systemic toxicity of peptide or drug delivery, the application is considered. The aims of this study were to manufactur chitosan nanoparticle containing HER-2 recombinant protein, evaluation of the properties and effect of its oral and injection immunization on spleen lymphocytes.

Materials and Methods: In this experimental study, pET-28a vector containing HER-2 gene was evaluated using PCR by universal primers. Expression of protein in E.coli was induced with IPTG. The recombinant protein was purified using affinity chromatography and evaluated by Western Blotting analysis. Chitosan nanoparticles containing recombinant protein were prepared by inonic gelation method and their size were characterized by DLS. Mice were immunized with nanoparticles and antibody titers were determined by ELISA. The response of lymphocytes in exposure to nanoparticles was evaluated by MTT assay. One way ANOVA, Duncan test and SPSS 22 software were used for statistical analysis.

Findings: The protein with a molecular weight of 18 kDa was confirmed. Yield of protein was 12mgL-1. Encapsulation efficiency of recombinant protein in nanoparticles was 70%. The average particle size was 205.2nm. Immunization of mice induced mucosal and humoral immune response.
Conclusion: Encapsulation efficiency of recombinant protein in nanoparticles is 70%. The average particle size is 205.2nm. Immunization of mice induces mucosal and humoral immune response HER-2 recombinant protein, due to the cellular and humoral immune response, is a candidate suitable for cancer diagnostic or therapeutic purposes.

Full-Text [PDF 639 kb]   (1561 Downloads)    
Article Type: Original Manuscipt | Subject: Biochemistry
Received: 2017/10/28 | Accepted: 2018/02/12

1. Soleimani N, Mohabati-Mobarez A, Atyabi F, Hasan-Saraf Z, Haghighi MA. Preparation of chitosan ‎nanoparticles carrying recombinant helicobacter pylori neutrophil-activating protein. J Mazandaran Univ ‎Med Sci. 2014;23(2):134-44. [Persian]‎ [Link]
2. Fazeli Z, Fazeli Bavandpour F, Abdi A, pour hosaingholi M, Akbari A, Salimian J. Trend analysis of breast ‎cancer mortality in Iranian women. J Ilam Univ Med Sci. 2013;20(4):246-251. [Persian]‎ [Link]
3. Zupančič E, Silva JM, Videira MA, Moreira JN, Florindo HF. Development of a novel nanoparticle-based ‎therapeutic vaccine for breast cancer immunotherapy. Proced Vaccinol. 2014;8:62-7.‎ [Link]
4. Daniele L, Sapino A. Anti-HER2 treatment and breast cancer: State of the art, recent patents, and new ‎strategies. Recent Pat Anticancer Drug Discov. 2009;4(1):9-18.‎ [Link]
5. Olayioye MA. Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ‎ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3(6):385-9.‎ [Link]
6. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer. ‎‎2008;44(18):2806-12.‎ [Link]
7. Ryu DW, Lee CH. impact of serum Her2 levels on survival and its correlation with clinicopathological ‎parametrs in women with breast cancer. J Breast Cancer. 2012;15(1):71-8.‎ [Link]
8. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with ‎advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet. ‎‎2008;102(2):128-13.‎ [Link]
9. Kaufmann R, Muller P, Hildenbrand G, Hausmann M, Cremer C. Analysis of Her2/neu membrane protein ‎clusters in different types of breast cancer cells using localization microscopy. J Microsc. 2011;242(1):46-54.‎ [Link]
10. Ross JS, Fletcher JA. The HER-2/neu Oncogene in breast cancer: Prognostic factor, predictive factor, and ‎target for therapy. Stem Cells. 1998;16(6):413-28.‎ [Link]
11. Tabatabaei-Panah AS, Zarnani AH, Montaser-Kouhsari Sh, Chamankhah M, Ghods R, Bayat AA, et al. ‎Production and characterization of Anti-Her2 monoclonal antibodies. Cell J (Yakhteh). 2008;10(2):109-120.‎ [Link]
12. Pecorino L. Molecular biology of cancer: Mechanisms, targets, and therapeutics. Oxford: OUP Oxford; ‎‎2012.‎ [Link]
13. Hajizade A, Ebrahimi F, Salmanian AH, Arpanaei A, Amani J. Nanoparticles in vaccine development. J ‎Appl Biotechnol Rep. 2014;1(4):125-34.‎ [Link]
14. Tan ML, Choong PF, Dass CR. Review: Doxorubicin delivery systems based on chitosan for cancer therapy. ‎J Pharm Pharmacol. 2009;61(2):131-42.‎ [Link]
15. Saremi S, Atyabi F, Akhlaghi SP, Ostad SN, Dinarvand R. Thiolated chitosan nanoparticles for enhancing ‎oral absorption of docetaxe preparation, in vitro and ex vivo evaluation. Int J Nanomedicine. 2011;6:119-28.‎ [Link]
16. Nystrom J, Svennerholm AM. Oral immunization with HpaA affords therapeutic protective immunity ‎against H. pylori that is reflected by specific mucosal immune responses. Vaccine. 2007;25(14):2591-8.‎ [Link]
17. Hosseinzadeh H, Atyabi F, Dinarvand R, Ostad SN. Chitosan-Pluronic nanoparticles as oral delivery of ‎anticancer gemcitabine: Preparation and in vitro study. Int J Nanomedicine. 2012;7:1851-63.‎ [Link]
18. Cooksley C, Jenks PJ, Green A, Cockayne A, Logan RP, Hardie KR. NapA protects Helicobacter pylori from ‎oxidative stress damage, and its production is influenced by the ferric uptake regulator. J Med Microbiol. ‎‎2003;52(Pt 6):461-9.‎ [Link]
19. Jabbal-Gill I, Watts P, Smith A. Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug ‎Deliv. 2012;9(9):1051-67.‎ [Link]
20. Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. ‎Pharm Res. 2011;28(2):215-36.‎ [Link]
21. Zhang HL, Wu SH, Tao Y, Zang LQ, Su ZhQ. Preparation and characterization of water-soluble chitosan ‎nanoparticles as protein delivery system. J Nanomater. 2010;2010:898910.‎ [Link]
22. Sambrok J, Russell DW. Molecular cloning a laboratory manual. 1st Volume. New York: Cold Spring Harbor ‎Laboratory Press; 2001.‎ [Link]
23. Iankov ID, Penheiter AR, Carlson SK, Galanis E. Development of monoclonal antibody-based ‎immunoassays for detection of Helicobacter pylori neutrophil-activating protein. J Immunol Methods. ‎‎2012;384(1-2):1-9.‎ [Link]
24. Bollag DM, Rozcki MD, Edelstein SJ. Protein methods. 2nd Edition. New York: Wiley-Liss; 1991.‎ [Link]
25. Amani J, Salmanian AH, Rafati S, Mousavi SL. Immunogenic properties of chimeric protein from espA, eae ‎and tir genes of Escherichia coli O157:H7. Vaccine. 2010;28(42):6923-9.‎ [Link]
26. Yousefpour P, Atyabi F, Dinarvand R. Vasheghani-Farahani E. Preparation and comparison of chitosan ‎nanoparticles with different degrees of glutathione thiolation. Daru. 2011;19(5):367-75.‎ [Link]
27. Grinberg O, Gedanken A, Patra CR, Patra S, Mukherjee P, Mukhopadhyay D. Sonochemically prepared ‎BSA microspheres containing Gemcitabine, and their potential application in renal cancer therapeutics. Acta ‎Biomater. 2009;5(8):3031-7.‎ [Link]
28. Yardel V, Seyed N, Mosaffa N. In-vitro production of anti LPS antibody by peritoneal and spleen B-‎Lymphocyte of Balb/c mice. Res Med. 2010;33(3):148-55. [Persian]‎ [Link]
29. Coveler AL, Bates NE, Disis ML. Progress in the development of a therapeutic vaccine for breast cancer. ‎Breast Cancer (Dove Med Press). 2010;2:25-36.‎ [Link]
30. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucins in the ‎pathogenesis of breast cancer: Implications in diagnosis, prognosis and therapy. Biochim Biophys Acta. ‎‎2011;1815(2):224-40.‎ [Link]
31. Kazemi M, Amani J, Salmanian AH, Forghanifard MM, Aghamollaei H. Design and expression of ‎recombinant HER-2 antigen as a marker for detection of breast cancer. Modares J Med Sci. 2015;17(4):88-‎‎99. [Persian]‎ [Link]
32. Sahoo N, Sahoo RK, Biswas N, Guha A, Kuotsu K. Recent advancement of gelatin nanoparticles in drug ‎and vaccine delivery. Int J Biol Macromol. 2015;81:317-31.‎ [Link]
33. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, et al. Nanoparticle vaccines. Vaccine. ‎‎2014;32(3):327-37.‎ [Link]
34. Smith A, Perelman M, Hinchcliffe M. Chitosan: A promising safe and immune-enhancing adjuvant for ‎intranasal vaccines. Hum Vaccin Immunother. 2014;10(3):797-807.‎ [Link]
35. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by ‎human dendritic cells in an in vitro model. Int J Pharm. 2005;298(2):315-22.‎ [Link]
36. Salehzadeh M, Norouzian P, Abbasali-Pourkabir R. The use of nanoparticles in diagnosis and treatment of ‎breast cancer: A review. Pajouhan Sci J. 2015;13(2):1-12. [Persian]‎ [Link]
37. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of ‎trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin ‎Oncol. 2002;20(3):719-26.‎ [Link]
38. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapyplus a ‎monoclonal antibody against HER2 for metastatic breastcancer that overexpresses HER2. N Engl J Med. ‎‎2001;344(11):783-92.‎ [Link]
39. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity ‎and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared ‎with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast ‎cancer. J Clin Oncol. 2001;19(5):1444-54.‎ [Link]
40. O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and ‎comparable effi cacy in a phase III trial of pegylated liposomal doxo rubicin HCL (Caelyxtm/DoxilR) versus ‎conventional doxorubicin for fi rst-line treatment of metastatic breast cancer. Anna Oncol. 2004;15(3):440-‎‎9.‎ [Link]
41. Shenoy DB, Amiji MM. Poly (ethylene oxide)-modified poly (epsilon-caprolactone) nanoparticles for ‎targeted delivery of tamoxifen in breast cancer. Int J Pharm. 2005;293(1-2):261-70.‎ [Link]
42. Vogel VG. Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol. ‎‎2001;19(18 Suppl):87S-92.‎ [Link]
43. Brown K. Breast cancer chemoprevention: Risk benefit effects of the antioestrogen tamoxifen. Expert ‎Opin Drug Saf. 2002;1(3):253-67.‎ [Link]
44. Sadeghi Aliabadi H, Karimimanesh A, Varshosaz J. Biological Effects of Letrozole-Loaded Lipid ‎Nanocapsules on MCF-7 Cell Line. J Isfahan Med Sci. 2013;30(217):2169-77. [Persian]‎ [Link]
45. Koohi Moftakhari Esfahani M, Alavi SE, Heidarinasab A, Chiani M, Akbarzadeh A. Making paclitaxel ‎nanoliposomal and evaluating its effect on the MCF-7. New Cell Mol Biotechnol J. 2013;3(10):67-71. ‎‎[Persian]‎ [Link]
46. Haghighi MA, Mohabati Mobarez A, Salmanian AH, Zali MR, Moazzeni SM, Karkhane AA. Application of ‎bioinformatics and genetic engineering for designing optimized cloning and overexpression of Neutrophil ‎activating protein of Helicobacter pylori in Escherichia Coli. J Zanjan Univ Med Sci. 2013;21(85):40-54. ‎‎[Persian]‎ [Link]
47. Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol. 2004;1(4):247-55.‎ [Link]
48. Kim‏ ‏MG, Park JY, Shon Y, Kim G, Shim G, Oh YK. Nanotechnology and vaccine development. Asian J ‎pharm Sci. 2014;9(5):227-35.‎ [Link]

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.